Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps [Yahoo! Finance]
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
5 million U.S. patients and no FDA-approved pharmacologic therapies — and said it is advancing regulatory discussions and seeking a partner to move belapectin forward. In the NAVIGATE study the composite primary endpoint was not met, but belapectin 2 mg/kg showed about a 50% reduction in new-onset esophageal varices versus placebo, favorable trends on medium/large varices, and an excellent safety profile. Belapectin, a galectin-3 inhibitor, produced supportive biomarker signals — including decreases in liver stiffness (VCTE), improvements in ELF and other fibrosis markers — consistent with antifibrotic activity that underpins further development. Interested in Galectin Therapeutics Inc.? Here are five stocks we like better. Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, a population the
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.GlobeNewswire
- Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ETGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTGlobeNewswire
GALT
Analyst Actions
- 12/17/25 - HC Wainwright
GALT
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 3
- 3/17/26 - Form 8-K
- GALT's page on the SEC website